Back to Publications

POGZ truncating alleles cause syndromic intellectual disability.

Specialty Areas:
Date: June 23, 2017
Authors:
Apostolos Psychogios, Arthur L. Beaudet, Christine Eng, Christine R. Beck, Daniel K. Arrington, Donna M. Muzny, Eric Boerwinkle, Fan Xia, James R. Lupski, Janice A. Baker, Janson White, Jennifer E. Posey, Jill A. Rosenfeld, Jing Zhang, Kati J. Mason, Kelly D. Farwell Hagman, Klaas J. Wierenga, Laura Fairbrother, Lynda Pollack, Magdalena Walkiewicz, Melissa Hall, Nancy J. Mendelsohn, Richard A. Gibbs, Richard E. Person, Shalini N. Jhangiani, Sha Tang, Tamar Harel, V. Reid Sutton, Yaping Yang, Zhiyv Niu, Zöe Powis
Journal: Genome medicine
Topics:
Read Abstract

Abstract

Background

Large-scale cohort-based whole exome sequencing of individuals with neurodevelopmental disorders (NDDs) has identified numerous novel candidate disease genes; however, detailed phenotypic information is often lacking in such studies. De novo mutations in pogo transposable element with zinc finger domain (POGZ) have been identified in six independent and diverse cohorts of individuals with NDDs ranging from autism spectrum disorder to developmental delay.

Methods

Whole exome sequencing was performed on five unrelated individuals. Sanger sequencing was used to validate variants and segregate mutations with the phenotype in available family members.

Results

We identified heterozygous truncating mutations in POGZ in five unrelated individuals, which were confirmed to be de novo or not present in available parental samples. Careful review of the phenotypes revealed shared features that included developmental delay, intellectual disability, hypotonia, behavioral abnormalities, and similar facial characteristics. Variable features included short stature, microcephaly, strabismus and hearing loss.

Conclusions

While POGZ has been associated with neurodevelopmental disorders in large cohort studies, our data suggest that loss of function variants in POGZ lead to an identifiable syndrome of NDD with specific phenotypic traits. This study exemplifies the era of human reverse clinical genomics ushered in by large disease-directed cohort studies; first defining a new syndrome molecularly and, only subsequently, phenotypically.